PPBT vs. NCNA, MBRX, INDP, ONTX, CNTX, MIRA, FBIO, SYBX, NERV, and XLO
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include NuCana (NCNA), Moleculin Biotech (MBRX), Indaptus Therapeutics (INDP), Onconova Therapeutics (ONTX), Context Therapeutics (CNTX), MIRA Pharmaceuticals (MIRA), Fortress Biotech (FBIO), Synlogic (SYBX), Minerva Neurosciences (NERV), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
Purple Biotech is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.
Purple Biotech's return on equity of -57.40% beat NuCana's return on equity.
9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Purple Biotech has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
In the previous week, NuCana had 14 more articles in the media than Purple Biotech. MarketBeat recorded 17 mentions for NuCana and 3 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 1.43 beat NuCana's score of 0.34 indicating that Purple Biotech is being referred to more favorably in the media.
NuCana received 236 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 91.67% of users gave Purple Biotech an outperform vote while only 67.49% of users gave NuCana an outperform vote.
Purple Biotech presently has a consensus price target of $9.00, suggesting a potential upside of 1,247.91%. NuCana has a consensus price target of $5.00, suggesting a potential upside of 1,834.24%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than Purple Biotech.
Summary
Purple Biotech and NuCana tied by winning 7 of the 14 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Purple Biotech Competitors List
Related Companies and Tools